SITE Centers to Present at the 2021 Citi Virtual Global Property CEO Conference

SITE Centers to Present at the 2021 Citi Virtual Global Property CEO Conference

BEACHWOOD, Ohio–(BUSINESS WIRE)–
SITE Centers Corp. (NYSE:SITC) today announced that it will participate in the 2021 Citi Virtual Global Property CEO Conference held March 8 through March 11, 2021. David R. Lukes, Chief Executive Officer, is scheduled to make a company presentation on Monday, March 8, 2021, at 8:15 a.m. Eastern Time. The audio-only webcast will be available to investors here, and the presentation deck will be posted on the Company’s website. A replay of the audio-only webcast will be available at ir.sitecenters.com through March 8, 2022.

About SITE Centers Corp.

SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC. Additional information about the Company is available at www.sitecenters.com. To be included in the Company’s e-mail distributions for press releases and other investor news, please click here.

Conor Fennerty

EVP and Chief Financial Officer

216-755-5500

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Retail Restaurant/Bar Department Stores Supermarket Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences:

H.C. Wainwright Global Life Sciences Conference

A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021.

33

rd

Annual Roth Conference

Date: March 15, 2021
Time: 5:30 p.m. ET
Format: Fireside Chat (live)

Oppenheimer 31

st

Annual Healthcare Conference

Date: March 16, 2021
Time: 4:30 p.m. ET
Format: Corporate Presentation (live)

Webcasts of the presentations will be available on the “Events and Presentations” section of the Clene website.

About Clene

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, has innovated a novel nanotechnology platform to create a new class of drugs—bioenergetic nanocatalysts. Clene’s lead drug candidate, CNM-Au8, is a concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the CNS. CNM-Au8 increases cellular energy to accelerate neurorepair and improve neuroprotection. Currently, CNM-Au8 is being investigated for efficacy and safety in a Phase 3 registration trial for ALS and in Phase 2 trials for multiple sclerosis and Parkinson’s disease. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Clene’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clene’s control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene’s reliance on third parties to conduct drug development, manufacturing and other services; Clene’s limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in Clene’s recently filed registration statement on Form S-4, as well as discussions of potential risks, uncertainties, and other important factors in Clene’s subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media Contact
Andrew Mielach
LifeSci Communications
(646) 876-5868
[email protected]

Investor Contact
Bruce Mackle
LifeSci Advisors, LLC
(929) 469-3859
[email protected]

Source: Clene Inc.



Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results

Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results

Quarterly revenue of $87.8 million, up 15.4% year over year

Fiscal year revenue of $326.8 million, up 16.3% year over year

Fiscal year operating cash flow of $42.1 million, up 107% year over year

2,487 active clients at December 31, 2020, up 20.6% year over year

LAS VEGAS–(BUSINESS WIRE)–Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced results for the fourth quarter and fiscal year ended December 31, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005039/en/

Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results (Graphic: Business Wire)

Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results (Graphic: Business Wire)

“For the fourth quarter and full year 2020, we continued to execute well against our strategic growth plan to achieve $1 billion in annual revenue by 2026 and exceeded quarterly and full year guidance. We accelerated year-over-year revenue growth for the fourth quarter from 11.7% to 15.4% and for the full year 2020 from 10.9% to 16.3%, respectively, achieved record quarterly and full year results for revenue, new sales invoicing, Calculated Billings, backlog and total gross profit and maintained a Revenue Retention rate of over 90 percent,” stated Seth A. Ravin, Rimini Street co-founder, CEO and chairman of the board. “Throughout the year, we continued making investments – including key executive leadership additions – to take advantage of growing global demand for Rimini Street’s support solutions, including our new application management, security, interoperability and professional services.”

“We produced another consecutive quarter of net income, further strengthened the balance sheet with record cash of $87.6 million at year end 2020 and generated $42.1 million of operating cash flow for full year 2020, a 107% year-over-year improvement,” stated Michael L. Perica, Rimini Street chief financial officer. “Today, we are issuing guidance for first quarter and full year 2021 revenue and affirming our continued commitment to the long-term goals of increasing operating cash flow and growing GAAP profitability.”

Additional details about the Company’s strategic growth plans and operations were presented during Rimini Street’s Investor Day 2021 on February 1, 2021, and the video and slide presentation materials can be found here on the Company’s Investor Relations page through January 2022.

Fourth Quarter 2020 Financial Highlights

  • Revenue was $87.8 million for the 2020 fourth quarter, an increase of 15.4% compared to $76.1 million for the same period last year.
  • Annual Recurring Revenue was $349 million for the 2020 fourth quarter, an increase of 15.4% compared to $302 million for the same period last year.
  • Active Clients as of December 31, 2020 were 2,487, an increase of 20.6% compared to 2,063 Active Clients as of December 31, 2019.
  • Revenue Retention Rate was 92% for both the trailing 12 months ended December 31, 2020 and for the comparable period ended December 31, 2019.
  • Gross margin was 61.8% for the 2020 fourth quarter compared to 60.2% for the same period last year.
  • Operating income was $4.5 million for the 2020 fourth quarter compared to $1.6 million for the same period last year.
  • Non-GAAP Operating Income was $11.9 million for the 2020 fourth quarter compared to $5.1 million for the same period last year.
  • Net income was $3.7 million for the 2020 fourth quarter compared to a net loss of $(0.2) million for the same period last year.
  • Non-GAAP Net Income was $11.1 million for the 2020 fourth quarter compared to $3.3 million for the same period last year.
  • Adjusted EBITDA for the 2020 fourth quarter was $12.9 million compared to $4.7 million for the same period last year.
  • Basic and diluted net loss per share attributable to common stockholders was $(0.04) for the 2020 fourth quarter compared to $(0.10) for the same period last year.
  • Employee count as of December 31, 2020 was 1,425, a year-over-year increase of 12%.

Full Year 2020 Financial Highlights

  • Revenue was $326.8 million for 2020, an increase of 16.3% compared to $281.1 million for 2019.
  • Gross margin was 61.4% for 2020 compared to 62.6% for 2019.
  • Operating income was $17.9 million for 2020 compared to $22.1 million for 2019.
  • Non-GAAP Operating Income was $41.1 million for 2020 compared to $26.8 million for 2019.
  • Net income was $13.0 million for 2020 compared to net income of $17.5 million for 2019.
  • Basic and diluted net loss per share attributable to common stockholders was $(0.19) per share for 2020 compared to $(0.12) for 2019.
  • Non-GAAP Net Income was $36.2 million for 2020 compared to $22.0 million for 2019.
  • Adjusted EBITDA was $42.6 million for 2020 compared to $27.0 million for 2019.
  • During the third quarter, the Company completed a follow-on public offering of approximately 6.1 million shares of common stock, with net proceeds to the Company of approximately $25.1 million.
  • During the fourth quarter, the Company repurchased $5 million face-value of Series A preferred and subsequent to the fourth quarter close, the Company repurchased an additional $10 million, for a total of $15 million face-value of Series A preferred stock at an approximate 10% discount to face-value; no make-whole payments were required and such preferred shares were retired.

Reconciliations of the non-GAAP financial measures provided in this press release to their most directly comparable GAAP financial measures are provided in the financial tables included at the end of this press release. An explanation of these measures, why we believe they are meaningful and how they are calculated is also included under the heading “About Non-GAAP Financial Measures and Certain Key Metrics.”

Full Year 2020 Company Highlights

  • Celebrated the 15th anniversary of the Company’s founding in 2005 to redefine the enterprise software support market and bring choice and value to software licensees around the world.
  • Saved clients more than $5 billion in total maintenance costs since the Company’s inception.
  • Launched the global availability of Rimini Street Support for SAP S/4HANA, extending the Company’s award-winning support services to S/4HANA licensees.
  • Announced the new patent pending Rimini Street Artificial Intelligence Support Applications, a result of the Company’s continued investment in optimizing support processes and ensuring global service delivery outcomes at scale. Using the AI Applications, Rimini Street has been able to deliver a better client experience and reduce software issue resolution times by 23%.
  • Further enhanced the Company’s industry-leading service response guarantee for clients, shortening response times for critical Priority 1 cases from 15 minutes to 10 minutes and for serious Priority 2 cases from 30 minutes to 15 minutes.
  • Closed more than 33,000 support cases and delivered nearly 89,000 tax, legal and regulatory updates for 58 countries, including more than 6,000 emergency updates related specifically to the global pandemic.
  • Achieved a record average client satisfaction rating on the Company’s support delivery of 4.9 out of 5.0 (where 5.0 is “excellent”), an increase from an average of 4.8/5.0 in 2019.
  • Appointed two new senior executive leaders to support the Company’s next phase of growth including:

    • Gerard Brossard to the newly created role of executive vice president and chief operating officer (COO); and
    • Michael L. Perica as executive vice president and chief financial officer (CFO).
  • Expanded the Company’s investment in Mexico and Central America, including the appointment of Alejandro González to the newly created role of general manager for the region.
  • Announced a whole-of-government volume sourcing agreement with the Australian government, designed to make the procurement process faster, easier and more cost-effective for agencies to access Rimini Street’s support services.
  • Awarded three Brazilian public sector contracts to support Oracle and SAP software as part of the government’s initiative to deliver transparency, efficiency, economy and optimization of public resources.
  • Announced that leading global automobile manufacturer, Hyundai-Kia Motors, significantly expanded its use of Rimini Street Oracle Database support to include its overseas branches and affiliates worldwide.
  • Announced that Green Cargo, the Swedish state-owned rail logistics operator, and Airservices Australia, Australia’s air navigation service provider, renewed their support agreements to continue to receive the Company’s ultra-responsive, high-quality support. Also announced many new clients from around the world including:

  • Honored with 33 awards, including two Gold Stevie Awards for “Company of the Year” and “Employer of the Year,” and 13 awards for customer service excellence.
  • Announced that the Company was named one of the Top 20 Companies to Work for in Las Vegas based on Rimini Street’s employee diversity, competitive salaries and financial health.
  • Presented at more than 50 CIO and IT and procurement leader events worldwide.
  • Supported more than 120 charities around the world through the Rimini Street Foundation, providing financial contributions, volunteer hours and in-kind donations including personal protective equipment to healthcare workers, senior centers, food banks and youth organizations globally. The Foundation also extended its charitable work in 2020 to Hong Kong, Malaysia, Mozambique, Sweden and the UAE.

2021 Revenue Guidance

The Company is providing first quarter 2021 revenue guidance to be in the range of $87.5 million to $88.5 million and full year 2021 revenue guidance to be in the range of $370 million to $380 million.

Webcast and Conference Call Information

Rimini Street will host a conference call and webcast to discuss the fourth quarter and full year 2020 results and select first quarter 2021 performance to-date commentary at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on March 3, 2021. A live webcast of the event will be available on Rimini Street’s Investor Relations site athttps://investors.riministreet.com. Dial-in participants can access the conference call by dialing (800) 708-4540 in the U.S. and Canada and enter the code 50079791. A replay of the webcast will be available for at least 90 days following the event.

Company’s Use of Non-GAAP Financial Measures

This press release contains certain “non-GAAP financial measures.” Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by U.S. generally accepted accounting principles, or GAAP. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures determined in accordance with GAAP. A reconciliation of GAAP to non-GAAP results is included in the financial tables included in this press release. Presented under the heading “About Non-GAAP Financial Measures and Certain Key Metrics” is a description and explanation of our non-GAAP financial measures.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,000 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (IR-RMNI)

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and economic, operational and financial impacts on our business of the COVID-19 pandemic impact, as well as the actions taken by us, governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on March 3, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

RIMINI STREET, INC.

Unaudited Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

   

ASSETS

 

December 31,

2020

 

December 31,

2019

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

87,575

 

 

$

37,952

 

Restricted cash

 

334

 

 

436

 

Accounts receivable, net of allowance of $723 and $1,608, respectively

 

117,937

 

 

111,574

 

Deferred contract costs, current

 

13,918

 

 

11,754

 

Prepaid expenses and other

 

13,456

 

 

15,205

 

Total current assets

 

233,220

 

 

176,921

 

Long-term assets:

 

 

 

 

Property and equipment, net of accumulated depreciation and amortization of $10,985 and $9,847, respectively

 

4,820

 

 

3,667

 

Operating lease right-of-use assets

 

17,521

 

 

 

Deferred contract costs, noncurrent

 

21,027

 

 

16,295

 

Deposits and other

 

1,476

 

 

3,089

 

Deferred income taxes, net

 

1,871

 

 

1,248

 

Total assets

 

$

279,935

 

 

$

201,220

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

Current liabilities:

 

 

 

 

Accounts payable

 

$

3,241

 

 

$

2,303

 

Accrued compensation, benefits and commissions

 

38,026

 

 

27,918

 

Other accrued liabilities

 

21,154

 

 

23,347

 

Operating lease liabilities, current

 

3,940

 

 

 

Deferred revenue, current

 

228,967

 

 

205,771

 

Total current liabilities

 

295,328

 

 

259,339

 

Long-term liabilities:

 

 

 

 

Deferred revenue, noncurrent

 

27,966

 

 

29,727

 

Operating lease liabilities, noncurrent

 

15,993

 

 

 

Accrued PIK dividends payable

 

1,193

 

 

1,156

 

Other long-term liabilities

 

2,539

 

 

2,275

 

Total liabilities

 

343,019

 

 

292,497

 

Redeemable Series A Preferred Stock:

 

 

 

 

Authorized 180 shares; issued and outstanding 155 shares and 155 as of December 31, 2020 and 2019, respectively. Liquidation preference of $154,911, net of discount of $17,057 and $155,231, net of discount of $23,915, as of December 31, 2020 and 2019, respectively

 

137,854

 

 

131,316

 

Stockholders’ Deficit:

 

 

 

 

Preferred Stock, $0.0001 par value per share. Authorized 99,820 shares (excluding 180 shares of Series A Preferred Stock); no other series has been designated

 

 

 

 

Common Stock, $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 76,406 and 67,503 shares as of December 31, 2020 and 2019, respectively

 

8

 

 

7

 

Additional paid-in capital

 

101,047

 

 

93,484

 

Accumulated other comprehensive loss

 

(318

)

 

(1,429

)

Accumulated deficit

 

(301,675

)

 

(314,655

)

Total stockholders’ deficit

 

(200,938

)

 

(222,593

)

Total liabilities, redeemable preferred stock and stockholders’ deficit

 

$

279,935

 

 

$

201,220

 

 

RIMINI STREET, INC.

Unaudited Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

   

 

 

Three Months Ended

 

Year Ended

 

 

December 31,

 

December 31,

 

 

2020

 

2019

 

2020

 

2019

Revenue

 

$

87,828

 

 

$

76,128

 

 

$

326,780

 

 

$

281,052

 

Cost of revenue

 

33,584

 

 

30,320

 

 

126,211

 

 

105,106

 

Gross profit

 

54,244

 

 

45,808

 

 

200,569

 

 

175,946

 

Operating expenses:

 

 

 

 

 

 

 

 

Sales and marketing

 

30,298

 

 

29,670

 

 

114,741

 

 

107,280

 

General and administrative

 

14,063

 

 

12,705

 

 

52,222

 

 

47,364

 

Impairment charges related to operating lease right-of-use assets

 

1,167

 

 

 

 

1,167

 

 

 

Litigation costs and related recoveries:

 

 

 

 

 

 

 

 

Professional fees and other costs of litigation

 

4,246

 

 

1,875

 

 

13,493

 

 

8,002

 

Litigation appeal refunds

 

 

 

 

 

 

 

(12,775

)

Insurance costs and recoveries, net

 

 

 

(61

)

 

1,062

 

 

3,939

 

Litigation costs and related recoveries, net

 

4,246

 

 

1,814

 

 

14,555

 

 

(834

)

Total operating expenses

 

49,774

 

 

44,189

 

 

182,685

 

 

153,810

 

Operating income

 

4,470

 

 

1,619

 

 

17,884

 

 

22,136

 

Non-operating income and (expenses):

 

 

 

 

 

 

 

 

Interest expense

 

(42

)

 

(23

)

 

(77

)

 

(398

)

Other income (expenses), net

 

473

 

 

(866

)

 

(258

)

 

(1,495

)

Income before income taxes

 

4,901

 

 

730

 

 

17,549

 

 

20,243

 

Income tax expense

 

(1,242

)

 

(937

)

 

(4,569

)

 

(2,714

)

Net income (loss)

 

$

3,659

 

 

$

(207

)

 

$

12,980

 

 

$

17,529

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(3,086

)

 

$

(6,780

)

 

$

(13,829

)

 

$

(7,914

)

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.04

)

 

$

(0.10

)

 

$

(0.19

)

 

$

(0.12

)

Weighted average number of shares of Common Stock outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

76,325

 

 

67,310

 

 

71,231

 

 

66,050

 

 

RIMINI STREET, INC.

GAAP to Non-GAAP Reconciliations

(In thousands)

   

 

 

Three Months Ended

 

Year Ended

 

 

December 31,

 

December 31,

 

 

2020

 

2019

 

2020

 

2019

Non-GAAP operating income reconciliation:

 

 

 

 

 

 

 

 

Operating income

 

$

4,470

 

 

$

1,619

 

 

$

17,884

 

 

$

22,136

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

4,246

 

 

1,814

 

 

14,555

 

 

(834

)

Stock-based compensation expense

 

2,036

 

 

1,704

 

 

7,461

 

 

5,532

 

Impairment charge related to operating lease right-of-use assets

 

1,167

 

 

 

 

1,167

 

 

 

Non-GAAP operating income

 

$

11,919

 

 

$

5,137

 

 

$

41,067

 

 

$

26,834

 

Non-GAAP net income reconciliation:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

3,659

 

 

$

(207

)

 

$

12,980

 

 

$

17,529

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

4,246

 

 

1,814

 

 

14,555

 

 

(834

)

Post-judgment interest in litigation awards

 

 

 

 

 

 

 

(212

)

Stock-based compensation expense

 

2,036

 

 

1,704

 

 

7,461

 

 

5,532

 

Impairment charge related to operating lease right-of-use assets

 

1,167

 

 

 

 

1,167

 

 

 

Non-GAAP net income

 

$

11,108

 

 

$

3,311

 

 

$

36,163

 

 

$

22,015

 

Non-GAAP Adjusted EBITDA reconciliation:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

3,659

 

 

$

(207

)

 

$

12,980

 

 

$

17,529

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

Interest expense

 

42

 

 

23

 

 

77

 

 

398

 

Income tax expense

 

1,242

 

 

937

 

 

4,569

 

 

2,714

 

Depreciation and amortization expense

 

493

 

 

452

 

 

1,813

 

 

1,913

 

EBITDA

 

5,436

 

 

1,205

 

 

19,439

 

 

22,554

 

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

4,246

 

 

1,814

 

 

14,555

 

 

(834

)

Post-judgment interest in litigation awards

 

 

 

 

 

 

 

(212

)

Stock-based compensation expense

 

2,036

 

 

1,704

 

 

7,461

 

 

5,532

 

Impairment charge related to operating lease right-of-use assets

 

1,167

 

 

 

 

1,167

 

 

 

Adjusted EBITDA

 

$

12,885

 

 

$

4,723

 

 

$

42,622

 

 

$

27,040

 

Calculated Billings:

 

 

 

 

 

 

 

 

Revenue

 

$

87,828

 

 

$

76,128

 

 

$

326,780

 

 

$

281,052

 

Deferred revenue, current and noncurrent, end of the period

 

256,933

 

 

235,498

 

 

256,933

 

 

235,498

 

Deferred revenue, current and noncurrent, beginning of the period

 

204,297

 

 

186,925

 

 

235,498

 

 

196,706

 

Change in deferred revenue

 

52,636

 

 

48,573

 

 

21,435

 

 

38,792

 

Calculated billings

 

$

140,464

 

 

$

124,701

 

 

$

348,215

 

 

$

319,844

 

About Non-GAAP Financial Measures and Certain Key Metrics

To provide investors and others with additional information regarding Rimini Street’s results, we have disclosed the following non-GAAP financial measures and certain key metrics. We have described below Active Clients, Annual Recurring Revenue and Revenue Retention Rate, each of which is a key operational metric for our business. In addition, we have disclosed the following non-GAAP financial measures: non-GAAP operating income, non-GAAP net income, EBITDA, adjusted EBITDA and Calculated Billings. Rimini Street has provided in the tables above a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Due to a valuation allowance for our deferred tax assets, there were no tax effects associated with any of our non-GAAP adjustments. These non-GAAP financial measures are also described below.

The primary purpose of using non-GAAP measures is to provide supplemental information that management believes may prove useful to investors and to enable investors to evaluate our results in the same way management does. We also present the non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, management uses these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware however, that not all companies define these non-GAAP measures consistently.

Calculated Billings represents the change in deferred revenue for the current period plus revenue for the current period.

Active Client is a distinct entity that purchases our services to support a specific product, including a company, an educational or government institution, or a business unit of a company. For example, we count as two separate active clients when support for two different products is being provided to the same entity. We believe that our ability to expand our active clients is an indicator of the growth of our business, the success of our sales and marketing activities, and the value that our services bring to our clients.

Annual Recurring Revenue is the amount of subscription revenue recognized during a fiscal quarter and multiplied by four. This gives us an indication of the revenue that can be earned in the following 12-month period from our existing client base assuming no cancellations or price changes occur during that period. Subscription revenue excludes any non-recurring revenue, which has been insignificant to date.

Revenue Retention Rate is the actual subscription revenue (dollar-based) recognized over a 12-month period from customers that were clients on the day prior to the start of such 12-month period, divided by our Annual Recurring Revenue as of the day prior to the start of the 12-month period.

Non-GAAP Operating Income is operating income adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and impairment charges related to right-of-use assets. The exclusions are discussed in further detail below.

Non-GAAP Net Income is net income adjusted to exclude: litigation costs and related recoveries, net, post-judgment interest in litigation awards, stock-based compensation expense and impairment charges related to operating lease right-of-use assets. These exclusions are discussed in further detail below.

Specifically, management is excluding the following items from its non-GAAP financial measures, as applicable, for the periods presented:

Litigation Costs and Related Recoveries, Net: Litigation costs and the associated insurance and appeal recoveries relate to outside costs of litigation activities. These costs and recoveries reflect the ongoing litigation we are involved with, and do not relate to the day-to-day operations or our core business of serving our clients.

Stock-Based Compensation Expense: Our compensation strategy includes the use of stock-based compensation to attract and retain employees. This strategy is principally aimed at aligning the employee interests with those of our stockholders and to achieve long-term employee retention, rather than to motivate or reward operational performance for any particular period. As a result, stock-based compensation expense varies for reasons that are generally unrelated to operational decisions and performance in any particular period.

Impairment charges related to operating lease right-of-use assets: An impairment charge related to our leased assets for a portion of one of our locations as we no longer use the space.

Post-judgment interest in litigation awards: Post-judgment interest resulted from our appeals of ongoing litigation and does not relate to the day-to-day operations or our core business of serving our clients.

EBITDA is net income adjusted to exclude: interest expense, income tax expense, and depreciation and amortization expense.

Adjusted EBITDA is EBITDA adjusted to exclude: litigation costs and related recoveries, net, post-judgment interest in litigation awards, stock-based compensation expense and impairment charges related to operating lease right-of-use assets, as discussed above.

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

[email protected]

Media Relations Contact

Michelle McGlocklin

Rimini Street, Inc.

+1 925 523-8414

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Logo
Logo
Photo
Photo
Rimini Street Announces Fiscal Fourth Quarter and Annual 2020 Financial Results (Graphic: Business Wire)

Global Medical REIT Announces Fourth Quarter and Year-End 2020 Financial Results

Global Medical REIT Announces Fourth Quarter and Year-End 2020 Financial Results

Completes $226.5 Million of Acquisitions in 2020

Increases First Quarter 2021 Dividend to $0.205 Per Share

BETHESDA, Md.–(BUSINESS WIRE)–
Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that owns and acquires purpose-built healthcare facilities and leases those facilities to strong healthcare systems and groups with leading market share, today announced financial results for the three and twelve months ended December 31, 2020 and other data.

Fourth Quarter 2020 Summary

  • Net income attributable to common stockholders was $1.1 million, or $0.02 per diluted share, as compared to $1.2 million, or $0.03 per diluted share, in the prior year period.
  • Funds from Operations (“FFO”) of $0.22 per share and unit, as compared to $0.21 per share and unit in the prior year period.
  • Adjusted Funds from Operations (“AFFO”) of $0.24 per share and unit, as compared to $0.21 per share and unit in the prior year period.
  • Increased total revenue 21.9% period-over-period to $24.9 million, primarily driven by the Company’s acquisition activity during 2020.
  • Renewed leases representing 7.1% of the Company’s annualized base rent (“ABR”) for a weighted average additional term of 9.2 years and extended the portfolio weighted average lease term to 8.2 years as of December 31, 2020.
  • Completed eight acquisitions, encompassing an aggregate 231,502 leasable square feet, for an aggregate purchase price of $79.8 million at a weighted average cap rate of 7.3%.
  • Issued 1.1 million shares of common stock at a weighted average price of $14.21 per share through its At-the-Market equity sales program (“ATM”), generating $15.3 million of gross proceeds.

Full-Year 2020 Summary

  • Net loss attributable to common stockholders was $(7.7) million, or $(0.17) per diluted share, which included a $12.1 million, or $0.26 per diluted share, one-time expense related to the management internalization consideration. This compares to net income attributable to common stockholders of $3.4 million, or $0.10 per diluted share, in the prior year.
  • FFO of $0.56 per share and unit, as compared to $0.75 per share and unit in the prior year.
  • AFFO of $0.88 per share and unit, as compared to $0.75 per share and unit in the prior year.
  • Increased total revenue 32.5% year-over-year to $93.7 million, primarily driven by acquisitions completed in 2020.
  • Completed 18 acquisitions, encompassing an aggregate 915,241 leasable square feet, for an aggregate purchase price of $226.5 million at a weighted average cap rate of 7.8%.
  • Issued 4.2 million shares of common stock at a weighted average price of $12.84 per share through its ATM program, generating $54.5 million of gross proceeds.

Jeffrey M. Busch, Chief Executive Officer stated, “We are pleased with our accomplishments for 2020 given the challenging environment due to the COVID-19 pandemic. We reached a milestone of growing our portfolio to over $1 billion in value, completed our internalization and completed 18 acquisitions for a total of $226 million at a 7.8% weighted average cap rate. We also successfully extended 7.1% of our ABR with four important lease renewals totaling 221,000 square feet. Finally, we announced our first quarterly dividend increase since the IPO.”

Mr. Busch continued, “Our portfolio proved to be highly resilient in the face of one of the most dramatic economic shocks in modern history. Our tenants remained open for business through the most challenging months of the healthcare crisis and, importantly, nearly all met their rent obligations to us. We are optimistic about what lies ahead given the deployment of the COVID-19 vaccine, our portfolio growth, and the future earnings accretion we expect from our internalization. We intend to continue our strategy of scaling our platform with properties and tenants that meet our underwriting criteria, growing AFFO per share, and providing our stockholders with a compelling total return over the long term.”

Financial Results

Rental revenue for the fourth quarter of 2020 increased 22.1% period-over-period to $24.9 million, reflecting the growth in the Company’s property portfolio.

Total expenses for the fourth quarter were $22.3 million, compared to $17.7 million for the prior year period.

  • G&A expenses for the fourth quarter of 2020 were $4.4 million, which compares to $1.6 million for the prior year period plus $1.7 million in management fees recognized in the prior year period. This increase in G&A expenses was primarily due to the recognition of compensation costs and other administrative expenses that prior to our internalization transaction were the obligation of our former advisor and included in our management fee. In addition, this increase reflects the impact of one-time LTIP Unit grants to the Company’s employees that were made at the time of our internalization transaction.
  • Depreciation and amortization expenses for the fourth quarter of 2020 were $10.1 million, compared to $7.4 million for the prior year period. This increase was primarily due to our acquisition activity during 2020.
  • Interest expense for the fourth quarter of 2020 was $5.1 million, compared to $4.8 million for the prior year period. This increase was primarily due to higher average borrowings during the fourth quarter, which helped fund our property acquisitions.

Net income attributable to common stockholders for the fourth quarter of 2020 totaled $1.1 million, or $0.02 per share, compared to a net income of $1.2 million, or $0.03 per share, in the prior year period.

The Company reported FFO of $0.22 per share and unit for the fourth quarter of 2020, as compared to $0.21 per share and unit in the prior year period. AFFO was $0.24 per share and unit for the fourth quarter of 2020 versus $0.21 per share and unit in the prior year period.

Portfolio Update

As of December 31, 2020, the Company’s portfolio was 99.1% occupied and comprised of 3.7 million leasable square feet with an ABR of $87.6 million. The Company’s portfolio rent coverage ratio was 4.8x. The Company’s portfolio had a weighted average lease term of 8.2 years and featured weighted average annual rental escalations of 2.1%.

Regarding rent collections, the Company has collected 99.5% of monthly base rent due for the fourth quarter of 2020.

Acquisitions Update

During the fourth quarter of 2020, the Company completed eight acquisitions, encompassing an aggregate 231,502 leasable square feet, for an aggregate purchase price of $79.8 million. The properties were purchased at a 7.3% weighted average cap rate.

For the full year 2020, the Company completed 18 property acquisitions, encompassing an aggregate 915,241 leasable square feet, for an aggregate purchase price of $226.5 million. The properties had a 7.8% weighted average cap rate at December 31, 2020.

Since December 31, 2020, the Company completed three acquisitions, encompassing an aggregate 86,035 leasable square feet, for an aggregate purchase price of $25.4 million. The properties were purchased at a 7.7% weighted average cap rate.

As of March 3, 2021, the Company had an additional six properties under contract for an aggregate purchase price of $75.7 million. The properties are currently in the due diligence period and we can make no assurances that the acquisitions will occur on a timely basis if at all.

Balance Sheet and Liquidity

At February 28, 2021, the Company had total liquidity of approximately $85 million, including cash and capacity on its Credit Facility.

At December 31, 2020, total debt outstanding, including outstanding borrowings on the Credit Facility and notes payable (both net of unamortized deferred financing costs), was $586.6 million. As of December 31, 2020, the Company’s debt carried a weighted average interest rate of 3.17% and a weighted average remaining term of 2.79 years.

During the fourth quarter of 2020, the Company issued 1.1 million shares of common stock through its ATM program at an average per share price of $14.21, generating gross proceeds of $15.3 million. For the full year 2020, the Company issued 4.2 million shares of common stock through its ATM program at an average per share price of $12.84, generating gross proceeds of $54.5 million.

Since December 31, 2020, the Company has issued 2.7 million shares of common stock through its ATM program at an average per share price of $13.07, generating gross proceeds of $35.4 million.

Dividends

On December 16, 2020, the Board of Directors declared the following dividends:

Dividend Type

Record Date

Dividend Amount

Payment Date

Common

December 28, 2020

$0.20 per share and unit

January 11, 2021

Preferred

January 15, 2021

$0.46875 per share

February 1, 2021

On March 2, 2021, the Board of Directors declared the following dividends:

Dividend Type

Record Date

Dividend Amount

Payment Date

Common

March 24, 2021

$0.205 per share and unit

April 8, 2021

Preferred

April 15, 2021

$0.46875 per share

April 30, 2021

2021 Annual Meeting

On March 2, 2021, the Board of Directors approved the meeting and record dates for the Company’s 2021 Annual Stockholders’ Meeting. The Meeting will be held on Wednesday, May 26, 2021. Stockholders of record as of April 1, 2021 will be eligible to vote at the Meeting.

SUPPLEMENTAL INFORMATION

Details regarding these results can be found in the Company’s supplemental financial package available on the Investor Relations section of the Company’s website at http://investors.globalmedicalreit.com/.

CONFERENCE CALL AND WEBCAST INFORMATION

The Company will host a live webcast and conference call on Thursday, March 4, 2021 at 9:00 a.m. Eastern Time. The webcast is located on the “Investor Relations” section of the Company’s website at http://investors.globalmedicalreit.com/.

To Participate via Telephone:

Dial in at least five minutes prior to start time and reference Global Medical REIT Inc.

Domestic: 1-877-705-6003

International: 1-201-493-6725

Replay:

A replay of the call will be available from approximately 12:00 p.m. Eastern Time on March 4, 2021, through midnight Eastern Time on March 18, 2021. To access the replay, the domestic dial-in number is 1-844-512-2921, the international dial-in number is 1-412-317-6671, and the passcode is 13715757. The archive of the webcast will be available on the Company’s website for a limited time.

ABOUT GLOBAL MEDICAL REIT

Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.

NON-GAAP FINANCIAL MEASURES

FFO and AFFO are non-GAAP financial measures within the meaning of the rules of the United States Securities and Exchange Commission (“SEC”). The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. In accordance with the National Association of Real Estate Investment Trusts’ (“NAREIT”) definition, FFO means net income or loss computed in accordance with GAAP before non-controlling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of deferred financing costs and above-market lease amortization expense), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of deferred financing costs and above market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company’s operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include: (a) management internalization costs (including a one-time expense related to the settlement of a pre-existing contractual relationship) (b) recurring acquisition and disposition costs, (c) loss on the extinguishment of debt, (d) recurring straight line deferred rental revenue, (e) recurring stock-based compensation expense, (f) recurring amortization of above market leases, (g) recurring amortization of deferred financing costs, (h) recurring lease commissions, and (i) other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis. The Company’s FFO and AFFO computations may not be comparable to FFO and AFFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, that interpret the NAREIT definition differently than the Company does, or that compute FFO and AFFO in a different manner.

RENT COVERAGE RATIO

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio (“Rent Coverage Ratio”), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 7% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) receipt of significant COVID-19 relief funds that may cause reported coverage to differ materially from underlying performance. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

ANNUALIZED BASE RENT

Annualized base rent represents December 31, 2020 base rent multiplied by 12 (or actual NOI for where more reflective of property performance).

FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “plan,” “predict,” “project,” “will,” “continue” and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, expected financial performance (including future cash flows associated with new tenants), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A – Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

Global Medical REIT Inc.

Condensed Consolidated Balance Sheets

(unaudited, and in thousands, except par values)

 

 

 

 

 

 

 

 

 

 

As of December 31,

 

 

 

2020

 

2019

 

Assets

 

 

 

 

 

 

 

Investment in real estate:

 

 

 

 

 

 

 

Land

 

$

128,857

 

$

95,381

 

Building

 

 

851,427

 

 

693,533

 

Site improvements

 

 

15,183

 

 

9,912

 

Tenant improvements

 

 

49,204

 

 

33,909

 

Acquired lease intangible assets

 

 

98,234

 

 

72,794

 

 

 

 

1,142,905

 

 

905,529

 

Less: accumulated depreciation and amortization

 

 

(94,462)

 

 

(56,503)

 

Investment in real estate, net

 

 

1,048,443

 

 

849,026

 

Cash and cash equivalents

 

 

5,507

 

 

2,765

 

Restricted cash

 

 

5,246

 

 

4,420

 

Tenant receivables, net

 

 

5,596

 

 

4,957

 

Due from related parties

 

 

103

 

 

50

 

Escrow deposits

 

 

4,817

 

 

3,417

 

Deferred assets

 

 

20,272

 

 

14,512

 

Derivative asset

 

 

 

 

2,194

 

Goodwill

 

 

5,903

 

 

 

Other assets

 

 

5,019

 

 

3,593

 

Total assets

 

$

1,100,906

 

$

884,934

 

 

 

 

 

 

 

 

 

Liabilities and Equity

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

Credit Facility, net of unamortized debt issuance costs of $3,559 and $3,832

at December 31, 2020 and December 31, 2019, respectively

 

$

521,641

 

$

347,518

 

Notes payable, net of unamortized debt issuance costs of $835 and $667 at

December 31, 2020 and December 31, 2019, respectively

 

 

64,937

 

 

38,650

 

Accounts payable and accrued expenses

 

 

7,279

 

 

5,069

 

Dividends payable

 

 

12,470

 

 

11,091

 

Security deposits and other

 

 

4,340

 

 

6,351

 

Due to related party

 

 

 

 

1,648

 

Derivative liability

 

 

18,086

 

 

8,685

 

Other liabilities

 

 

6,171

 

 

2,405

 

Acquired lease intangible liability, net

 

 

8,222

 

 

3,164

 

Total liabilities

 

 

643,146

 

 

424,581

 

Commitments and Contingencies

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000 shares authorized; 3,105 issued and

outstanding at December 31, 2020 and December 31, 2019, respectively

(liquidation preference of $77,625 at December 31, 2020 and

December 31, 2019, respectively)

 

 

74,959

 

 

74,959

 

Common stock, $0.001 par value, 500,000 shares authorized; 49,461 shares and

43,806 shares issued and outstanding at December 31, 2020 and

December 31, 2019, respectively

 

 

49

 

 

44

 

Additional paid-in capital

 

 

504,789

 

 

433,330

 

Accumulated deficit

 

 

(116,773)

 

 

(71,389)

 

Accumulated other comprehensive loss

 

 

(18,219)

 

 

(6,674)

 

Total Global Medical REIT Inc. stockholders’ equity

 

 

444,805

 

 

430,270

 

Noncontrolling interest

 

 

12,955

 

 

30,083

 

Total equity

 

 

457,760

 

 

460,353

 

Total liabilities and equity

 

$

1,100,906

 

$

884,934

Global Medical REIT Inc.

Condensed Consolidated Statements of Operations

(unaudited, and in thousands, except per share amounts)

         
   

Three Months Ended

   

Twelve Months Ended

   

December 31,

   

December 31,

   

2020

 

 

 

2019

 

 

 

2020

 

 

 

2019

Revenue

               

Rental revenue

 

$

 

24,895

 

$

 

20,385

 

$

 

93,518

 

$

 

70,515

Other income

   

35

   

67

   

212

   

211

Total revenue

   

24,930

   

20,452

   

93,730

   

70,726

                 

Expenses

               

General and administrative

   

4,426

   

1,608

   

11,935

   

6,536

Operating expenses

   

2,612

   

2,132

   

10,867

   

5,958

Management fees – related party

   

   

1,727

   

4,024

   

6,266

Depreciation expense

   

7,364

   

5,585

   

26,747

   

19,066

Amortization expense

   

2,774

   

1,812

   

9,606

   

5,569

Interest expense

   

5,064

   

4,765

   

18,680

   

17,472

Management internalization expense

   

   

   

14,005

   

Preacquisition expense

   

98

   

48

   

365

   

271

Total expenses

   

22,338

   

17,677

   

96,229

   

61,138

                 

Net income (loss)

 

$

 

2,592

 

$

 

2,775

 

$

 

(2,499)

 

$

 

9,588

Less: Preferred stock dividends

   

(1,455)

   

(1,455)

   

(5,822)

   

(5,822)

Less: Net (income) loss attributable to noncontrolling interest

   

(74)

   

(108)

   

574

   

(354)

Net income (loss) attributable to common stockholders

 

$

 

1,063

 

$

 

1,212

 

$

 

(7,747)

 

$

 

3,412

   

 

   

 

   

 

   

 

Net income (loss) attributable to common stockholders per share

– basic and diluted

 

$

 

0.02

 

$

 

0.03

 

$

 

(0.17)

 

$

 

0.10

                 

Weighted average shares outstanding – basic and diluted

   

48,496

   

37,876

   

46,256

   

33,865

Global Medical REIT Inc.

Reconciliation of Net Income (Loss) to FFO and AFFO

(unaudited, and in thousands, except per share and unit amounts)

         
   

Three Months Ended

   

Twelve Months Ended

   

December 31,

   

December 31,

   

2020

 

 

 

2019

 

 

 

2020

 

 

 

2019

                 

Net income (loss)

 

$

 

2,592

 

$

 

2,775

 

$

 

(2,499)

 

$

 

9,588

Less: Preferred stock dividends

   

(1,455)

   

(1,455)

   

(5,822)

   

(5,822)

Depreciation and amortization expense

   

10,112

   

7,397

   

36,302

   

24,635

FFO

 

$

 

11,249

 

$

 

8,717

 

$

 

27,981

 

$

 

28,401

Internalization expense – settlement of a preexisting contractual relationship

   

   

   

12,094

   

Internalization expense – other transaction costs

   

   

   

1,911

   

Amortization of above market leases, net

   

32

   

247

   

504

   

881

Straight line deferred rental revenue

   

(1,344)

   

(1,492)

   

(5,680)

   

(5,806)

Stock-based compensation expense

   

1,928

   

843

   

5,319

   

3,336

Amortization of debt issuance costs and other

   

420

   

312

   

1,450

   

1,312

Preacquisition expense

   

98

   

48

   

365

   

271

AFFO

 

$

 

12,383

 

$

 

8,675

 

$

 

43,944

 

$

 

28,395

                 

Net income (loss) attributable to common stockholders per share –

               

basic and diluted

 

$

 

0.02

 

$

 

0.03

 

$

 

(0.17)

 

$

 

0.10

FFO per Share and Unit

 

$

 

0.22

 

$

 

0.21

 

$

 

0.56

 

$

 

0.75

AFFO per Share and Unit

 

$

 

0.24

 

$

 

0.21

 

$

 

0.88

 

$

 

0.75

                 

Weighted Average Shares and Units Outstanding – basic and diluted

   

52,076

   

41,794

   

49,791

   

37,789

                 

Reconciliation of Weighted Average Shares and Units Outstanding:

               

Weighted Average Common Shares

   

48,496

   

37,876

   

46,256

   

33,865

Weighted Average OP Units

   

1,941

   

3,143

   

2,172

   

3,144

Weighted Average LTIP Units

   

1,639

   

775

   

1,363

   

780

Weighted Average Shares and Units Outstanding – basic and diluted

   

52,076

   

41,794

   

49,791

   

37,789

 

Investor Relations:

Evelyn Infurna

[email protected]

203.682.8265

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Professional Services Health Hospitals Commercial Building & Real Estate Finance Construction & Property REIT

MEDIA:

Steelcase to Webcast Fourth Quarter and Fiscal 2021 Conference Call

GRAND RAPIDS, Mich., March 03, 2021 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) will webcast a discussion of its fourth quarter and fiscal year 2021 financial results on Wednesday, March 24, 2021 at 8:30 a.m. ET. A link to the webcast will be available at http://ir.steelcase.com and a replay of the webcast will be available shortly after the call concludes. The news release detailing the financial results will be issued the previous day, March 23, 2021, after the market closes. 

About Steelcase Inc. 
For over 108 years, Steelcase Inc. has helped create great experiences for the world’s leading organizations, across industries. We demonstrate this through our family of brands – including Steelcase®, Coalesse®, Designtex®, Turnstone®, Smith System®, Orangebox® and AMQ®. Together, they offer a comprehensive portfolio of architecture, furniture and technology products and services designed to unlock human promise and support social, economic and environmental sustainability. We are globally accessible through a network of channels, including approximately 800 Steelcase dealer locations. Steelcase is a global, industry-leading and publicly traded company with fiscal 2020 revenue of $3.7 billion.

Investor Contact: Media Contact:
Mike O’Meara Katie Woodruff
Investor Relations Corporate Communications
(616) 292-9274 (616) 915-8505



Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on March 1, 2021, the Company granted non-qualified stock options to purchase an aggregate of 54,250 shares of the Company’s common stock to seven newly hired employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incentive Plan, were approved by the Company’s Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $23.80 per share, equal to the closing price of Translate Bio’s common stock on March 1, 2021. Each stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on March 1, 2022 and in thirty-six equal monthly installments thereafter as to the remaining shares. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Stock Incentive Plan.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes that its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Investor Relations  Media Relations
Teri Dahlman              Maura Gavaghan
Tel.: +1 (617) 817-8655                             Tel: +1 (617) 233-1154
[email protected]          [email protected]                 



Retrotope to Present at H.C. Wainwright Global Life Sciences Conference

LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) — Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that Anil Kumar, president and chief business officer, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Sciences Conference. The conference, which will take place March 9-10, 2021, is being conducted with a virtual format.

Details for the corporate presentation are as follows:

  • H.C. Wainwright Global Life Sciences Conference
    Details: Retrotope management will deliver a corporate presentation and participate in 1-on-1 meetings
    Conference dates: March 9-10, 2021
    Format: Virtual conference

About Retrotope

Retrotope is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for degenerative diseases ranging from orphan neurodegenerative indications to large market degenerative conditions. The company leverages its proprietary drug discovery platform to create novel, disease-modifying drugs designed to combat the oxidative stress and cellular degeneration that arises from lipid peroxidation (LPO). It does so through the creation of isotopically stabilized synthetic versions of polyunsaturated fatty acids (PUFAs) that trigger the downregulation of the LPO process. The company’s lead development candidate, RT001, is a clinical-stage isotopically stabilized, synthetic linoleic acid (LA) that is in development for a range of orphan neurodegenerative diseases, including infantile neuroaxonal dystrophy (INAD), Friedreich’s ataxia (FA), amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and progressive supranuclear palsy (PSP). In addition, the company is advancing its second development candidate, RT011, an isotopically stabilized, synthetic docosahexaenoic acid (DHA), toward the clinic for the treatment of dry age-related macular degeneration (AMD).

For more information, please visit www.retrotope.com.



Contacts:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
[email protected] 

Tim Brons (Media)
415-675-7402 
[email protected]

LPL Financial to Present at the Wolfe Virtual FinTech Forum 2021

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) — Leading retail investment advisory firm and independent broker-dealer LPL Financial LLC, a wholly-owned subsidiary of LPL Financial Holdings Inc. (Nasdaq: LPLA), today announced that Chief Financial Officer Matt Audette will present at the Wolfe Virtual FinTech Forum 2021 on March 10.

The virtual presentation takes place at 1:40 p.m. ET. A live audio webcast of the presentation will be accessible at investor.lpl.com, with a replay available on the website beginning two hours after the presentation. The replay will remain available through March 31.


About LPL Financial


LPL Financial (Nasdaq: LPLA) was founded on the principle that the firm should work for the advisor, and not the other way around. Today, LPL is a leader* in the markets we serve, supporting more than 17,000 financial advisors, 800 institution-based investment programs and 450 independent RIA firms nationwide. We are steadfast in our commitment to the advisor-centered model and the belief that Americans deserve access to objective guidance from a financial advisor. At LPL, independence means that advisors have the freedom they deserve to choose the business model, services, and technology resources that allow them to run their perfect practice. And they have the freedom to manage their client relationships, because they know their clients best. Simply put, we take care of our advisors, so they can take care of their clients.

* Top RIA custodian (Cerulli Associates, 2019 U.S. RIA Marketplace Report)
No. 1 Independent Broker-Dealer in the U.S (Based on total revenues, Financial Planning magazine June 1996-2020)
No. 1 provider of third-party brokerage services to banks and credit unions (2019-2020 Kehrer Bielan Research & Consulting Annual TPM Report)

Securities and Advisory services offered through LPL Financial LLC, a registered investment advisor. Member FINRA/SIPC. We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

Investor Relations – Chris Koegel, (617) 897-4574
Media Relations – Lauren Hoyt-Williams, (980) 321-1232
investor.lpl.com/contactus.cfm



Hudson Technologies Reports Fourth Quarter 2020 Results

PEARL RIVER, N.Y., March 03, 2021 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced results for the fourth quarter and year ended December 31, 2020.

For the quarter ended December 31, 2020, Hudson reported revenues of $22.1 million, a decrease of 14% compared to revenues of $25.8 million in the comparable 2019 period. The decrease in revenue was primarily due to decreased volume, as the COVID-19 pandemic and the associated closures of public venues such as commercial and recreational facilities, schools and universities across the U.S. negatively impacted the Company’s end markets and overall demand for refrigerants for much of the year, partially offset by an increase in selling price of certain refrigerants. Gross margin in the fourth quarter of 2020 was 25%, compared to 19% in the fourth quarter of 2019, mainly due to the aforementioned increase in selling price of certain refrigerants. Hudson reported an operating loss of $1.7 million in the fourth quarter of 2020 compared to an operating loss of $4.8 million in the prior year period. The Company recorded a net loss of $4.7 million or ($0.11) per basic and diluted share in the fourth quarter of 2020, compared to a net loss of $10.8 million or ($0.25) per basic and diluted share in the same period of 2019.
    
For the year ended December 31, 2020, Hudson reported revenues of $147.6 million, a decrease of 9% compared to $162.1 million in 2019. The decrease in revenue was primarily due to decreased volume, related to the pandemic-driven closures described above. Gross margin for full year 2020 improved to 24% compared to gross margin of 11% for the full year 2019. The Company reported operating income of $5.9 million for 2020 compared to an operating loss of $15.8 million in 2019. The Company’s net loss for 2020 was $5.2 million, or ($0.12) per basic and diluted share, compared to a net loss of $25.9 million, or ($0.61) per basic and diluted share in 2019, which included a $9.2 million non-cash inventory adjustment mainly due to declines in selling prices of certain refrigerants during that time period.

Brian F. Coleman, President and Chief Executive Officer of Hudson Technologies commented, “2020 was a challenging year for our industry, characterized by the public health and economic uncertainties caused by the global COVID-19 pandemic. As we begin 2021, we are optimistic that the widespread closures related to the virus will begin to subside and enable the broader re-opening of our economy. With that in mind, we are planning and preparing for the 2021 selling season so that we are ready to meet potential demand as more cooling systems return to operation and we look forward to fully re-engaging with our customers as they continue to come back online.”

Conference Call Information

The Company will host a conference call and webcast to discuss the fourth quarter results today, March 3, 2021 at 5:00 P.M. Eastern Time.

To access the live webcast, log onto the Hudson Technologies website at www.hudsontech.com, and click on “Investor Relations”.

To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528-0011. Callers should use entry code: 227063.

A replay of the teleconference will be available until April 3, 2021 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 40141.

About Hudson Technologies         

Hudson Technologies, Inc. is a leading provider of innovative and sustainable solutions for optimizing performance and enhancing reliability of commercial and industrial chiller plants and refrigeration systems. Hudson’s proprietary RefrigerantSide® Services increase operating efficiency, provide energy and cost savings, reduce greenhouse gas emissions and the plant’s carbon footprint while enhancing system life and reliability of operations at the same time. RefrigerantSide® Services can be performed at a customer’s site as an integral part of an effective scheduled maintenance program or in response to emergencies. Hudson also offers SMARTenergy OPS®, which is a cloud-based Managed Software as a Service for continuous monitoring, fault detection and diagnostics and real-time optimization of chilled water plants. In addition, the Company sells refrigerants and provides traditional reclamation services for commercial and industrial air conditioning and refrigeration uses. For further information on Hudson, please visit the Company’s web site at www.hudsontech.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changes in the laws and regulations affecting the industry, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company’s ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, the ability to meet financial covenants under existing credit facilities, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the Company may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, the impact of the current COVID-19 pandemic, and other risks detailed in the Company’s 10-K for the year ended December 31, 2019 and other subsequent filings with the Securities and Exchange Commission. The words “believe”, “expect”, “anticipate”, “may”, “plan”, “should” and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.



Investor Relations Contact:


John Nesbett/Jennifer Belodeau
IMS Investor Relations
(203) 972-9200
[email protected]



Company Contact:


Brian F. Coleman, President & CEO
Hudson Technologies, Inc.
(845) 735-6000
[email protected]

  

Hudson Technologies, Inc. and Subsidiaries

Consolidated Balance Sheets

(Amounts in thousands, except for share and par value amounts)

    December 31,  
    2020     2019  

Assets
               
Current assets:                
Cash and cash equivalents   $ 1,348     $ 2,600  
Trade accounts receivable – net     9,806       8,061  
Inventories     44,460       59,238  
Prepaid expenses and other current assets     6,528       4,525  
Total current assets     62,142       74,424  
                 
Property, plant and equipment, less accumulated depreciation     21,910       23,674  
Goodwill     47,803       47,803  
Intangible assets, less accumulated amortization     23,150       26,012  
Right of use asset     6,559       8,048  
Other assets     85       192  
Total Assets   $ 161,649     $ 180,153  
                 

Liabilities and Stockholders’ Equity
               
Current liabilities:                
Trade accounts payable   $ 7,644     $ 10,274  
Accrued expenses and other current liabilities     19,417       18,120  
Accrued payroll     1,394       724  
Current maturities of long-term debt     7,314       3,008  
Short-term debt     2,000       14,000  
Total current liabilities     37,769       46,126  
Deferred tax liability     1,355       1,192  
Long-term lease liabilities     3,927       5,742  
Long-term debt, less current maturities, net of deferred financing costs     77,976       81,982  
Total Liabilities     121,027       135,042  
                 
Commitments and contingencies                
                 
Stockholders’ equity:                
Preferred stock, shares authorized 5,000,000: Series A Convertible preferred stock, $0.01 par value ($100 liquidation preference value); shares authorized 150,000; none issued or outstanding            
Common stock, $0.01 par value; shares authorized 100,000,000; issued and outstanding: 43,347,887 and 42,628,560, respectively     433       426  
Additional paid-in capital     118,269       117,557  
Accumulated deficit     (78,080 )     (72,872 )
Total Stockholders’ Equity     40,622       45,111  
                 
Total Liabilities and Stockholders’ Equity   $ 161,649     $ 180,153  
                 

Hudson Technologies, Inc. and Subsidiaries

Consolidated Statements of Operations

(unaudited)
(Amounts in thousands, except for share and per share amounts)

    Three months

ended December 31,
    Twelve months

ended December 31,
 
    2020     2019     2020     2019  
                         
Revenues   $ 22,110     $ 25,753     $ 147,605     $ 162,059  
Cost of sales     16,684       20,989       112,195       144,894  
Gross profit     5,426       4,764       35,410       17,165  
                                 
Operating expenses:                                
Selling, general and administrative     6,460       8,864       26,644       30,018  
Amortization     715       715       2,862       2,931  
Total operating expenses     7,175       9,579       29,506       32,949  
                                 
Operating income (loss)     (1,749 )     (4,815 )     5,904       (15,784 )
                                 
Other expense:                                
Interest expense     (2,918 )     (5,990 )     (12,330 )     (18,911 )
Other income (expense)     22       (1 )     1,033       9,411  
Total other expense     (2,896 )     (5,991 )     (11,297 )     (9,500 )
                                 
Loss before income taxes     (4,645 )     (10,806 )     (5,393 )     (25,284 )
                                 
Income tax expense (benefit)     103       (35       (185 )     656  
                                 
Net loss   $ (4,748 )   $ (10,771 )   $ (5,208 )   $ (25,940 )
                                 
Net loss per common share – Basic   $ (0.11 )   $ (0.25 )   $ (0.12 )   $ (0.61 )
Net loss per common share – Diluted   $ (0.11 )   $ (0.25 )   $ (0.12 )   $ (0.61 )
Weighted average number of shares outstanding – Basic     42,881,307       42,628,560       42,710,381       42,613,478  
Weighted average number of shares outstanding – Diluted     42,881,307       42,628,560       42,710,381       42,613,478  



CTO Realty Growth Announces Acquisition of 183,000 Square Foot Retail Property in Salt Lake City, Utah for $20.0 Million

DAYTONA BEACH, Fla., March 03, 2021 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the acquisition of an approximately 183,000 square foot multi-tenant retail property in the West Jordan suburb of Salt Lake City, Utah (the “Property”) for a purchase price of approximately $20.0 million, or $117 per square foot. The purchase price represents a going-in cap rate within the range of the Company’s guidance for initial cash yields.

“We are pleased to be entering the growing Salt Lake City MSA, which represents a new market for CTO, and we’re particularly excited about the strong positioning of this property,” said John P. Albright, President and Chief Executive Officer of CTO Realty Growth. “Based on data provided by our third-party data analytics service, we believe this property benefits by being centrally located within a particularly strong retail corridor, representing a great piece of real estate in our growing diversified portfolio.”

The Property, which is 93% occupied and has a weighted-average lease term of approximately 7.9 years, is situated within the Jordan Landing retail corridor and is anchored by At Home, Burlington and Planet Fitness. The Property benefits from a three-mile population of approximately 143,000, average household income of nearly $105,000, and visibility along the UT-154 expressway, which experiences an average of more than 55,000 vehicles per day.

The Property was purchased through a 1031 like-kind exchange using restricted cash generated from the Company’s previously announced property dispositions.


About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. is a publicly traded diversified REIT that owns and operates a diversified portfolio of income properties comprising approximately 2.7 million square feet in the United States. CTO also owns an approximate 23.5% interest in Alpine Income Property Trust, Inc., a publicly traded net lease REIT (NYSE: PINE).

We encourage you to review our most recent investor presentation, which is available on our website at www.ctoreit.com.


Safe Harbor

Certain statements contained in this press release (other than statements of historical fact) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can typically be identified by words such as “believe,” “estimate,” “expect,” “intend,” “anticipate,” “will,” “could,” “may,” “should,” “plan,” “potential,” “predict,” “forecast,” “project,” and similar expressions, as well as variations or negatives of these words.

Although forward-looking statements are made based upon management’s present expectations and reasonable beliefs concerning future developments and their potential effect upon the Company, a number of factors could cause the Company’s actual results to differ materially from those set forth in the forward-looking statements. Such factors may include, but are not limited to: the Company’s ability to remain qualified as a REIT; the Company’s exposure to U.S. federal and state income tax law changes, including changes to the REIT requirements; general adverse economic and real estate conditions; the ultimate geographic spread, severity and duration of pandemics such as the recent outbreak of the novel coronavirus, actions that may be taken by governmental authorities to contain or address the impact of such pandemics, and the potential negative impacts of such pandemics on the global economy and the Company’s financial condition and results of operations; the inability of major tenants to continue paying their rent or obligations due to bankruptcy, insolvency or a general downturn in their business; the loss or failure, or decline in the business or assets of PINE or the venture formed when the Company sold its controlling interest in the entity that owned the Company’s remaining land portfolio, of which the Company has a retained interest; the completion of 1031 exchange transactions; the availability of investment properties that meet the Company’s investment goals and criteria; the uncertainties associated with obtaining required governmental permits and satisfying other closing conditions for planned acquisitions and sales; and the uncertainties and risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, each as filed with the SEC.

There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact: Matthew M. Partridge
  Senior Vice President and Chief Financial Officer
  (386) 944-5643
  [email protected]